https://visitsync.app 2026-04-02T18:07:54.554Z weekly 1 https://visitsync.app/auth/login 2026-04-02T18:07:54.554Z monthly 0.8 https://visitsync.app/auth/register 2026-04-02T18:07:54.554Z monthly 0.8 https://visitsync.app/privacy 2026-04-02T18:07:54.554Z yearly 0.3 https://visitsync.app/terms 2026-04-02T18:07:54.554Z yearly 0.3 https://visitsync.app/hipaa 2026-04-02T18:07:54.554Z yearly 0.4 https://visitsync.app/contact 2026-04-02T18:07:54.554Z monthly 0.6 https://visitsync.app/blog 2026-04-02T18:07:54.554Z daily 0.7 https://visitsync.app/blog/nice-approves-wegovy-for-cardiovascular-protection-1m-uk-patients-eligible 2026-04-02T08:01:19.118108+00:00 weekly 0.6 https://visitsync.app/blog/fda-approves-avlayah-for-hunter-syndrome-cns-treatment-breakthrough 2026-04-01T08:01:08.364641+00:00 weekly 0.6 https://visitsync.app/blog/cardinal-health-webcol-recall-microbial-contamination-alert-for-clinics 2026-03-27T08:01:05.611567+00:00 weekly 0.6 https://visitsync.app/blog/resistant-hypertension-trial-explores-minimally-invasive-procedure-options 2026-03-26T08:01:04.723287+00:00 weekly 0.6 https://visitsync.app/blog/enhertu-secures-new-japanese-approvals-implications-for-global-oncology-mn5r86nz 2026-03-25T08:01:06.294035+00:00 weekly 0.6 https://visitsync.app/blog/fda-seeks-public-input-on-national-priority-voucher-pilot-program-mn4bsbvy 2026-03-24T08:01:06.172497+00:00 weekly 0.6 https://visitsync.app/blog/fda-approves-imcivree-for-hypothalamic-obesity-clinical-breakthrough-mn2wcjdt 2026-03-23T08:01:09.107894+00:00 weekly 0.6 https://visitsync.app/blog/fda-advances-animal-testing-alternatives-with-new-nams-draft-guidance-mn1gwmrh 2026-03-22T08:01:06.605731+00:00 weekly 0.6 https://visitsync.app/blog/fiercemadness-2026-why-drug-naming-matters-for-clinical-research-mn01gpv2 2026-03-21T08:01:03.547943+00:00 weekly 0.6 https://visitsync.app/blog/fda-approves-higher-dose-wegovy-new-72mg-semaglutide-for-weight-management-mmym0vpq 2026-03-20T08:01:04.64128+00:00 weekly 0.6 https://visitsync.app/blog/icotyde-approval-jjs-oral-tyk2-inhibitor-transforms-psoriasis-treatment-mmx6kzzg 2026-03-19T08:01:02.864705+00:00 weekly 0.6 https://visitsync.app/blog/fda-accelerates-biosimilar-development-to-lower-healthcare-costs-mmvr59z3 2026-03-18T08:01:08.870548+00:00 weekly 0.6 https://visitsync.app/blog/lillys-ebglyss-shows-promise-for-pediatric-atopic-dermatitis-expansion-mmubpcvy 2026-03-17T08:01:05.738479+00:00 weekly 0.6 https://visitsync.app/blog/fda-unveils-aems-new-unified-platform-for-adverse-event-transparency-mmsw9fys 2026-03-16T08:01:03.089992+00:00 weekly 0.6 https://visitsync.app/blog/fda-warning-letter-highlights-critical-manufacturing-compliance-gaps-mmrgtlwd 2026-03-15T08:01:03.672153+00:00 weekly 0.6 https://visitsync.app/blog/fda-approves-wellcovorin-for-cerebral-folate-transport-deficiency-mmq1dpnt 2026-03-14T08:01:01.587618+00:00 weekly 0.6 https://visitsync.app/blog/lilly-raises-safety-concerns-over-compounded-tirzepatide-impurities-mmoly2jx 2026-03-13T08:01:11.355471+00:00 weekly 0.6 https://visitsync.app/blog/fda-approves-tec-dara-under-priority-voucher-program-for-multiple-myeloma-mmn6i06m 2026-03-12T08:01:01.508804+00:00 weekly 0.6 https://visitsync.app/blog/fda-issues-warning-letter-to-novo-nordisks-us-operations-mmlr26i4 2026-03-11T08:01:02.624074+00:00 weekly 0.6 https://visitsync.app/blog/fda-state-collaboration-on-drug-importation-implications-for-research-mmiw6eiq 2026-03-09T08:00:59.203365+00:00 weekly 0.6 https://visitsync.app/blog/senate-democrats-demand-evidence-of-trump-drug-pricing-deal-benefits-mmhgqp0k 2026-03-08T08:01:05.875941+00:00 weekly 0.6 https://visitsync.app/blog/fda-approves-first-true-generic-flovent-market-impact-for-asthma-care-mmeluz83 2026-03-06T08:01:05.291458+00:00 weekly 0.6 https://visitsync.app/blog/fda-cracks-down-on-30-telehealth-companies-over-compounded-glp-1-marketing-mmd6f27l 2026-03-05T08:01:02.228764+00:00 weekly 0.6 https://visitsync.app/blog/merck-scales-back-gardasil-production-amid-global-demand-decline-mm8w3pgq 2026-03-02T08:01:11.665246+00:00 weekly 0.6 https://visitsync.app/blog/strategic-partnerships-drive-next-gen-drug-delivery-innovation-in-2025-mm7gnns0 2026-03-01T08:01:02.537456+00:00 weekly 0.6 https://visitsync.app/blog/global-clinical-trials-pharmas-strategic-response-to-geopolitics-mm617wgi 2026-02-28T08:01:07.090737+00:00 weekly 0.6 https://visitsync.app/blog/fda-approves-second-drug-under-new-priority-voucher-program-for-lung-cancer-mm4lrvgt 2026-02-27T08:00:58.691606+00:00 weekly 0.6 https://visitsync.app/blog/fdas-new-framework-revolutionizes-ultra-rare-disease-drug-development-mm0bgd5p 2026-02-24T08:01:00.922285+00:00 weekly 0.6 https://visitsync.app/blog/catalents-maryland-layoffs-signal-broader-gene-therapy-manufacturing-shift-mlxgkpbx 2026-02-22T08:01:02.863757+00:00 weekly 0.6 https://visitsync.app/blog/fda-moves-to-restrict-non-approved-glp-1-compounds-impact-on-research-mlw14wwf 2026-02-21T08:01:05.770604+00:00 weekly 0.6 https://visitsync.app/blog/trumps-mfn-drug-pricing-plan-faces-conservative-resistance-mlt695qh 2026-02-19T08:01:03.445361+00:00 weekly 0.6 https://visitsync.app/blog/fdas-new-natural-colors-policy-clinical-research-implications-mlrqtbvd 2026-02-18T08:01:04.475767+00:00 weekly 0.6 https://visitsync.app/blog/trump-administration-revives-340b-rebate-pilot-what-cros-need-to-know-mlovxoen 2026-02-16T08:01:06.837152+00:00 weekly 0.6 https://visitsync.app/blog/fda-reassessment-of-bha-what-clinical-researchers-need-to-know-mlnghweu 2026-02-15T08:01:10.416779+00:00 weekly 0.6 https://visitsync.app/blog/fda-approves-revolutionary-device-for-locally-advanced-pancreatic-cancer-mlm11sps 2026-02-14T08:00:58.596211+00:00 weekly 0.6 https://visitsync.app/blog/fda-updates-hrt-labeling-new-risk-clarifications-for-clinical-practice-mll6ssi4 2026-02-13T17:54:09.931938+00:00 weekly 0.6